NEW YORK, March 12 - CuraGen and Alexion Pharmaceuticals on Tuesday said they have signed a deal to discover and validate cancer-related biologic and small-molecule drug targets.

Terms of the multi-year agreement, which may grow in the future to include other diseases, call for CuraGen to apply its functional genomic technologies to help Alexion identify drug targets from data the biotech company will provide.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

An analysis has examined the makeup of researchers on Twitter and what they share, Nature News reports.

At Stat News, Jim Kozubek argues that the Broad Institute is pushing the boundary of what a nonprofit is.

In PNAS this week: gut microbes may affect honeybee weight, phenotype and gene expression changes in DiGeorge syndrome, and more.

Vivek Murthy is no longer the surgeon general of the US, the Associated Press reports.